• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

    2/6/25 7:00:00 AM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VYGR alert in real time by email

    LEXINGTON, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will participate in a fireside chat at the Oppenheimer 25th Annual Healthcare Life Sciences Conference at 2:40 p.m. ET on February 11, 2025.

    A webcast of the presentation will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.

    About Voyager Therapeutics

    Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.

    Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

    Contacts

    Trista Morrison, NACD.DC, [email protected]

    Investors: Mike Hencke, [email protected]   

    Media: Brooke Shenkin, [email protected]



    Primary Logo

    Get the next $VYGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VYGR

    DatePrice TargetRatingAnalyst
    1/10/2025Overweight
    Cantor Fitzgerald
    12/2/2024$12.00Buy
    Citigroup
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    10/16/2024$15.00Outperform
    Leerink Partners
    3/26/2024$22.00Buy
    Guggenheim
    3/19/2024$30.00Buy
    H.C. Wainwright
    3/7/2024$16.00Buy
    Citigroup
    1/2/2024$14.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Voyager Therapeutics

      Cantor Fitzgerald initiated coverage of Voyager Therapeutics with a rating of Overweight

      1/10/25 9:15:32 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Voyager Therapeutics with a new price target

      Citigroup initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $12.00

      12/2/24 7:04:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush resumed coverage on Voyager Therapeutics with a new price target

      Wedbush resumed coverage of Voyager Therapeutics with a rating of Outperform and set a new price target of $11.00 from $7.00 previously

      11/29/24 7:27:18 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Voyager Therapeutics Inc.

      10-Q - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:02:24 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)

      5/6/25 4:01:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Voyager Therapeutics Inc.

      DEFA14A - Voyager Therapeutics, Inc. (0001640266) (Filer)

      4/23/25 4:02:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 6:13:11 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 5:12:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      8/7/24 4:10:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Financials

    Live finance-specific insights

    See more

    $VYGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

      - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's di

      3/31/25 7:00:47 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

      - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

      3/11/25 4:01:00 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

      LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

      3/4/25 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

      LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

      6/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

      LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through

      3/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ferguson Toby sold $34,595 worth of shares (10,086 units at $3.43), decreasing direct ownership by 6% to 157,914 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:10:01 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Sandrock Alfred sold $37,336 worth of shares (10,885 units at $3.43), decreasing direct ownership by 2% to 430,931 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      4/4/25 4:08:51 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Carter Todd Alfred sold $14,079 worth of shares (3,305 units at $4.26) and was granted 46,000 shares, increasing direct ownership by 53% to 123,718 units (SEC Form 4)

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      2/24/25 4:21:45 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care